This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Chinese Hepatitis B Vaccine Industry - Deep Research Report 2013

DUBLIN, Nov. 26, 2013 /PRNewswire/ -- Research and Markets ( has announced the addition of the "Chinese Hepatitis B Vaccine Industry - Deep Research Report 2013" report to their offering.

(Logo: ) This 2013 Deep Research Report is a professional and in-depth research report on the Chinese Hepatitis B Vaccine industry. This report firstly discusses Hepatitis B vaccine definition, classification, industry chain, manufacturing technology and product specifications. The report then gives statistics on major Chinese Hepatitis B vaccine manufacturers including details on capacity, production, supply, demand, shortage, selling price, cost, gross margin and production value. The report gives information on 8 Chinese manufacturers such as basic company information, production price, cost, gross margin, production value and Chinese market share. In the end, this report discusses the 10million pieces/year Hepatitis B vaccine project feasibility analysis and investment return analysis, and gives related research conclusions and development trend analysis. Key Topics Covered: 1 Hepatitis B Vaccine Industry Overview 1.1 Definition 1.2 Classification Application Work Principle and Related Content 1.3 Industry Chain Structure 1.4 Market Status and Development Trend 1.5 Policy Analysis 2 Hepatitis B Vaccine Manufacturing Process and Cost Analysis 2.1 Product Speficiation 2.2 Manufacturing Process Analysis 2.3 Cost Structure Analysis 2.4 Raw Materials and Equipments Overview 2.5 Technical Trend and Difficulties 3 Hepatitis B Vaccine Production Supply Sales Demand Market Status and Forecast 3.1 Hepatitis B Vaccine Capacity and Production 3.2 Hepatitis B Vaccine Different Type(Saccharomyces Cerevisiae:5ug 10ug 20ug 60ug,CHO Cell:10ug 20ug,Hansenula Polymorpha:10ug) Capacity and Production 3.3 Children Adult Type Hepatitis B Vaccine Production Overview 3.4 Beijing Shenzhen Liaoning Hebei Shandong Henan etc Different Regions Hepatitis B Vaccine Production Overview 3.5 Hepatitis B Vaccine Capacity Utilization Rate Analysis 3.6 Hepatitis B Vaccine Demand Overview 3.7 Hepatitis B Vaccine Supply Demand Shortage 3.8 Hepatitis B Vaccine Cost Price Production Value Gross Margin 3.9 Hepatitis B Vaccine Import Export Consumption 3.10 Hepatitis B Vaccine Batch Release Number Statistics 4 Hepatitis B Vaccine Key Manufacturers 4.1 Beijing Tiantan Biological Products Co.,Ltd (600161) 4.2 Shenzhen Kaitai Biological 4.3 Dalian Hissen Biological 4.4 NCPC GeneTech Biotechnology 4.5 Beijing Huaerdun Biotechnology 4.6 Hualan Biological(002007) 4.7 GSK 4.8 Berna Biotech 5 Hepatitis B Vaccine New Project Investment Feasibility Analysis 5.1 Hepatitis B Vaccine New Project SWOT Analysis 5.2 10 Million Pieces/Year Hansenula Polymorpha YeastHepatitis B Vaccine (Type:10ug) Project Investment Feasibility Analysis 6 Hepatitis B Vaccine Industry Research Conclusions

Companies Mentioned

  • Berna Biotech
  • Beijing Huaerdun Biotechnology
  • Beijing Tiantan Biological Products Co.,Ltd (600161)
  • Dalian Hissen Biological
  • GSK
  • Hualan Biological(002007)
  • NCPC GeneTech Biotechnology
  • Shenzhen Kaitai Biological

For more information visit

Media Contact:

Laura Wood , +353-1-481-1716,

SOURCE Research and Markets

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs